Survival Benefit of Perioperative Systemic Chemotherapy for Patients With N0 to N1 NSCLC Having Synchronous Brain Metastasis

Survival Benefit of Perioperative Systemic Chemotherapy for Patients With N0 to N1 NSCLC Having Synchronous Brain Metastasis

Introduction: In stage IV NSCLC with solitary or oligometastatic brain metastasis, surgical resection of the primary and definitive management of the brain metastasis is an accepted standard. However, the effect of systemic chemotherapy after surgical resection on overall survival is not well-establ...

Full description

Bibliographic Details
Main Authors: Yeshwanth R. Vedire, MD, Sarah Shin, MD, Adrienne Groman, MS, Mark Hennon, MD, Grace K. Dy, MD, Sai Yendamuri, MD
Format: Article
Language:English
Published: Elsevier 2023-06-01
Series:JTO Clinical and Research Reports
Subjects:
lung cancer
brain metastasis
adjuvant therapy
chemotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323000619

Internet

http://www.sciencedirect.com/science/article/pii/S2666364323000619

Similar Items